相关临床试验
71
50 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
48
67.6%
已完成
1
1.4%
尚未招募
2
2.8%
招募中
20
28.2%
暂无批准数据
- A longitudinal study of 502 children from the GUSTO birth cohort found that higher screen viewing at age 1 showed the strongest association with poorer later academic performance and weaker working memory. - Screen exposure at ages 2 and 3 showed no significant links, but associations re-emerged at age 6, coinciding with the transition into formal schooling. - Researchers suggest infancy and the start of formal education may be sensitive periods when screen habits carry longer-term implications for learning and memory. - The authors emphasize that "less is better" for screen exposure and call for future research on content quality, device type, and parental co-viewing.
- French scientists at INSERM's ART lab in Orleans are pioneering a breakthrough approach combining mRNA vaccines with ultrasound technology to penetrate pancreatic cancer's protective barrier. - The innovative technique uses ultrasound to create gas bubbles that destroy the tumor's surrounding barrier, allowing mRNA vaccines to effectively reach and teach immune cells to fight the aggressive cancer. - Pancreatic cancer survival rates have improved only marginally from 5% to 10% over two decades, highlighting the urgent need for new therapeutic approaches beyond conventional chemotherapy and immunotherapy. - The research is part of a global surge in mRNA cancer therapeutics, with over 200 clinical trials currently underway worldwide, expanding beyond the COVID-19 vaccine applications that earned the 2023 Nobel Prize in Medicine.
- Researchers from Institut Pasteur and Inserm developed a triple therapy using clinically approved drugs that forces malignant B cells to undergo necroptosis, an immunogenic form of cell death that activates the immune system. - The combination overcomes a key barrier where malignant B cells lack the MLKL protein essential for necroptosis, successfully triggering powerful immune responses that completely eliminated leukemia in preclinical models. - Real-time imaging revealed how necroptotic cancer cell death releases danger signals that recruit immune cells like macrophages and T cells, effectively turning dying tumor cells into an in situ vaccine. - This approach represents a paradigm shift in immunotherapy by demonstrating that the manner of tumor cell death is as critical as inducing death itself for therapeutic efficacy against B cell malignancies.
- Researchers from King's College London and France's INSERM developed a needle-free vaccine delivery method using gentle skin stretching that opens hair follicles and enhances permeability. - The skin stretching technique itself acts as an immune enhancer by triggering inflammatory responses and recruiting immune cells including dendritic cells, neutrophils, and macrophages. - Flu vaccine delivered via this method produced stronger antibody responses in mice compared to traditional intramuscular injection, demonstrating superior vaccine efficacy. - The technology could potentially be applied to deliver various biopharmaceuticals including cell therapies and polymer drugs without pain or needles.
- Major international medical research funders have signed a joint statement committing to implement WHO standards for strengthening clinical trial systems globally. - The initiative aims to integrate clinical trials into sustainable national infrastructure while improving trial design and ensuring representative patient populations. - Funders will require trials to be registered in public registries, publish results within 12 months, and meet transparency standards for data sharing. - Within six months, signatories will develop measurable indicators to track progress and ensure accountability across the global research community.
- Okeiro (formerly Predict4Health) has raised €10 million in funding led by Alven, Forepont Capital Partners, and Red River West to expand its AI-powered clinical decision support platform internationally. - The company's proprietary iBox algorithm, recognized as a surrogate endpoint by FDA and EMA, enables early prediction of transplant rejection and has already been implemented in leading French transplant centers. - Okeiro is conducting a multi-center randomized clinical trial across 16 hospitals in 6 countries to validate its technology's effectiveness compared to standard care protocols.
- MSInsight has raised €1.6 million in seed funding to develop MSIcare, an AI-powered diagnostic solution that significantly improves detection accuracy for Microsatellite Instability (MSI) cancers. - Current diagnostic methods for MSI cancers lead to errors in up to 30% of cases, while MSInsight's technology leverages next-generation sequencing to provide more precise results and guide appropriate immunotherapy treatment. - The funding will enable MSInsight to finalize MSIcare's development, demonstrate its performance across various cancer types, and pursue CE-IVD regulatory certification as an in vitro diagnostic medical device.
- A landmark randomized controlled trial by MatriceLab Innove demonstrates that personalized treatment based on endometrial immune profiling increases IVF live birth rates from 29.7% to 41.4%. - The study shows particularly impressive results for challenging cases, with live birth rates nearly doubling for patients with suboptimal embryos and those with multiple failed transfers. - The UTIMPRO endometrial immune profiling test identified immune dysregulation in 78% of study participants, suggesting immune factors play a crucial role in IVF success.
- Initiating antiretroviral therapy (ART) within weeks of HIV infection may allow for long-term viral control even after treatment is stopped, according to a new study. - The research, conducted on primates with SIV, demonstrated that early ART for two years optimized immune cell development, enhancing their ability to combat the virus. - A delay in treatment initiation by just a few months diminished the benefits, highlighting the importance of early HIV detection and intervention. - The findings suggest a 'window of opportunity' exists for promoting HIV remission through early treatment, reinforcing the need to scale up testing and treatment services.
